Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) just unveiled an update.
China Resources Pharmaceutical Group Ltd. announced significant changes in its executive leadership, effective August 26, 2025. Mr. Tao Ran has resigned from his roles as executive director and member of the Executive Committee, while Mr. Cheng Jie has been appointed as the new executive director, president, and member of both the Executive and Corporate Governance Committees. These changes are expected to influence the company’s strategic direction, leveraging Mr. Cheng’s extensive experience in the pharmaceutical sector and his leadership roles within the company’s subsidiaries.
The most recent analyst rating on (HK:3320) stock is a Buy with a HK$7.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Ltd. is a prominent player in the pharmaceutical industry, focusing on the production and distribution of medical and healthcare products. The company is involved in various segments, including over-the-counter (OTC) drugs, prescription drugs, and traditional Chinese medicine, with a significant market presence in China.
Average Trading Volume: 12,295,656
Technical Sentiment Signal: Sell
Current Market Cap: HK$32.23B
For detailed information about 3320 stock, go to TipRanks’ Stock Analysis page.